Clinical Trial Results:
A PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN PATIENTS METASTATIC OR UNRESECTABLE LOCALLY-ADVANCED THYROID CANCER REFRACTORY TO, OR NOT SUITABLE CANDIDATES FOR 131I TREATMENT
Summary
|
|
EudraCT number |
2006-002576-18 |
Trial protocol |
CZ IT ES |
Global completion date |
24 Sep 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Mar 2016
|
First version publication date |
06 Feb 2015
|
Other versions |
|
Summary report(s) |
A4061027 EU Posting |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.